LYCOS RETRIEVER 
Genetics: Decode Genetics
built 624 days ago
Iceland's deCODE Genetics is suing five former employees for allegedly stealing research knowledge and trade secrets and using them at Children's Hospital in Philadelphia. And the biotech company says the theft was done with the knowledge of the hospital staff, an allegation the hospital denies. Hakon Hakonarson, deCODE's former vice president of business development, is named in the suit along with four others recruited by the Center for Applied Genomics, which is part of Children's …
Source:
REYKJAVIK, Iceland, Jan. 9 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced positive topline results from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. With these results, the company has finalized the design of a Phase IIb trial for which it expects to begin enrolling patients this spring. The company will discuss the development of DG051 and the rest of its product portfolio in its presentation at the JP Morgan 26th Annual Healthcare Conference. The presentation, to be delivered on Thursday January 10 at 11:30am PST/2:30pm EST/7:30pm GMT, will be webcast live via the investors' section of the company's website at www.decode.com.
Source:
PRINCETON, N.J., June 12 /PRNewswire/ -- Medarex's partner, Genmab A/S, announced today that Genmab and Medarex have formed a major alliance with deCODE genetics. Under the alliance, the companies intend to generate fully human antibodies to multiple disease targets derived from deCODE's genetic research. Genmab, Medarex and deCODE plan to investigate a range of potential therapeutics, including those for inflammatory and cardiovascular diseases as well as cancer. Given the scope of this multi-target alliance, Medarex will contribute resources to the collaboration and will share certain costs and commercial rights. Medarex has licensed its human antibody technology to Genmab and has an agreement in which it may participate with Genmab in multi-target European genomics relationships. Separately Genmab ... announced today a pharmacogenomics alliance with deCODE for the development of a DNA-based test that could determine the clinical response of a particular treatment in individual patients.
Source:
The cornerstone of quality for those in the field, OMMBID has been updated by an elite editorial team and a group of contributors representing a Who's Who of medical genetics. Contributors include primary decoders of the human genome and the researchers currently working on the human phenome project-the next great discovery in molecular medicine. These same contributors will ... supply continuous content updates, marked by chapter for immediate identification.
Source:
"This is the latest in a series of landmark papers from deCODE in which we have utilized our unique capabilities in human genetics to elucidate some of the key mechanisms driving human evolution," said Kari Stefansson, CEO of deCODE. "We are ... excited that we can now immediately enable individuals to see if they carry such variants, by folding the findings announced today -- and others we expect to publish in the near future -- into our deCODEme(TM) personal genome analysis service."
Source:
MORE ABOUT
Decode Genetics